Want to see CV full AI Analyst Report?
CV Stock Chart & Stats
$6.49
$0.12(1.85%)
At close: 4:00 PM EDT
$6.49
$0.12(1.85%)
Day’s Range― - ―
52-Week Range$3.43 - $15.37
Previous Close$6.74
Volume83.71K
Average Volume (3M)45.47K
Market Cap
$322.55M
Enterprise Value$370.14
Total Cash (Recent Filing)$9.08M
Total Debt (Recent Filing)$687.00K
Price to Earnings (P/E)―
Beta-1.55
Next Earnings
Nov 12, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding50,046,913
10 Day Avg. Volume21,973
30 Day Avg. Volume45,470
Financial Highlights & Ratios
PEG Ratio-0.77
Price to Book (P/B)37.78
Price to Sales (P/S)36.96
P/FCF Ratio-21.83
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.52
Revenue Forecast (FY)$15.57M
Bulls Say, Bears Say
Bulls Say
Platform Adoption And Recurring UtilizationDouble-digit capsule and patient growth indicates rising clinician utilization and broader adoption of the platform. Because capsules are disposable and procedure-linked, sustained volume expansion can support recurring revenue and deepen the installed workflow base.
Intellectual Property And Commercial ReachA healthy gross-margin profile, proprietary software and 85 U.S. patents provide a foundation for retaining economics as the company scales. Renewals and expansion in hospital systems and GI networks can improve reach and make the platform harder to displace.
AI Product And Pipeline ExpansionInternational AI Highlights commercialization and advancing Colon and UGI programs broaden the diagnostic offering beyond the current capsule product. FDA milestones, if achieved, could add differentiated workflow tools and new indications over the next 2–6 months.
Bears Say
Persistent Cash Burn And Funding DependencePersistent operating and free-cash-flow deficits mean the business is not self-funding. Continued burn can require additional equity or other financing, limiting strategic flexibility and creating dilution risk as management funds commercialization and development.
Margin And Operating-Leverage PressureQ2 operating expenses rose sharply while gross margin fell and ASP declined. If development, public-company and commercialization costs remain elevated while pricing stays pressured, revenue growth may not translate into durable operating leverage.
Regulatory And Product-Timing RiskThe AI Highlights 510(k) requires additional demographic information, with clearance not guaranteed, while the Colon submission moved to Q4. These dependencies can delay U.S. monetization and extend investment before pipeline products contribute materially.
CapsoVision, Inc. News
CV FAQ
What was CapsoVision, Inc.’s price range in the past 12 months?
CapsoVision, Inc. lowest stock price was $3.43 and its highest was $15.37 in the past 12 months.
What is CapsoVision, Inc.’s market cap?
CapsoVision, Inc.’s market cap is $322.55M.
When is CapsoVision, Inc.’s upcoming earnings report date?
CapsoVision, Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 85 days.
How were CapsoVision, Inc.’s earnings last quarter?
CapsoVision, Inc. released its earnings results on Aug 13, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.02.
Is CapsoVision, Inc. overvalued?
According to Wall Street analysts CapsoVision, Inc.’s price is currently Overvalued.
Does CapsoVision, Inc. pay dividends?
CapsoVision, Inc. does not currently pay dividends.
What is CapsoVision, Inc.’s EPS estimate?
CapsoVision, Inc.’s EPS estimate is -0.14.
How many shares outstanding does CapsoVision, Inc. have?
CapsoVision, Inc. has 50,046,913 shares outstanding.
What happened to CapsoVision, Inc.’s price movement after its last earnings report?
CapsoVision, Inc. reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -4.86%.
Which hedge fund is a major shareholder of CapsoVision, Inc.?
Currently, no hedge funds are holding shares in CV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CapsoVision, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
CV Sentiment 100%
Sector Average 62%
Sector Average 62%
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
108.43%
Trailing 12-Months
Company Description
CapsoVision, Inc.
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
CV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of constructive commercial and product-development progress — including double-digit unit and patient-growth, the international launch of AI Highlights, meaningful pipeline milestones, and initiatives to secure financing — alongside notable near-term challenges such as margin compression, a decline in average selling price, a substantial increase in operating expenses, competitive and tariff pressures, and regulatory/timing uncertainty for U.S. clearance and product submissions.View all CV earnings summariesTechnical Analysis
Ownership Overview
8.62% Insiders
3.17% Mutual Funds
0.02% Other Institutional Investors
83.01% Public Companies and
Individual Investors